Highlights in myasthenia gravis from AAN 2025 include trials of new therapy inebilizumab, new data on the approved ...

The desire for patients to have a personalized approach to care is repeated throughout the ad, which was produced by Avalere ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Shares of argenx (NASDAQ:ARGX) traded ~14% lower on Thursday after the maker of myasthenia gravis therapy, Vyvgart, missed ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...